Skip to main content
Fig. 4 | Respiratory Research

Fig. 4

From: LPA1 antagonist BMS-986020 changes collagen dynamics and exerts antifibrotic effects in vitro and in patients with idiopathic pulmonary fibrosis

Fig. 4

ECM-neoepitope biomarker CFB measurements in patients with IPF from the phase 2 trial NCT01766817. Patient numbers for each ECM-neoepitope biomarker stratified by treatment group and time point are indicated. BID twice daily; BL baseline; CFB change from baseline; ECM extracellular matrix; IPF idiopathic pulmonary fibrosis; QD once daily; SEM standard error of the mean; WK week. ECM-neoepitope biomarker abbreviations are defined in Table 1

Back to article page